Delivery Courier? Microglia Drop Neprilysin Off Near Plaques in Brain
The cells reduced the amount of amyloid and improved downstream aspects of Alzheimer’s pathogenesis in mouse models.
ALL NEWS
56 RESULTS
Sort By:
- Most Recent
- Most Commented
Trontinemab Fuels Hope for Brain Shuttle Lift-Off
The TfR-targeted, anti-Aβ antibody swiftly axed amyloid throughout the brain. It caused little ARIA, but lots of infusion reactions.
Will We Soon Stage Alzheimer’s With Plasma Markers?
Tau fragments, alone or with other proteins, help identify people with lots of tangles. This may help select people for trials or therapy.
Blood Tests: Not Just for the Impaired?
Real-world data hints that plasma markers can pick up Alzheimer’s pathology before people have memory complaints.
Looking Good: Immunoassays for Blood Markers
Fully automated test may be as accurate as mass spec, and more scalable.
Tau PET as Progression Marker: It’s the Spread, Not the Brightness
The spatial extent of tau pathology better correlates with disease severity, and stages disease more accurately, than does tangle load.
Commander Complexes in Lysosomes Stave Off Parkinson’s Risk
Decreased lysosomal efficiency could result from shifts in endosomal recycling.
Trial-Eligible Genetic Variants Now Marked in Alzforum Mutations Database
DIAN-TU explains how it selects APP, PSEN1, and PSEN2 genetic variants for clinical trial inclusion.
Trialists Grapple with How to Outsmart TREM2
After one TREM2 agonist antibody nose-planted, a new batch of therapies appear safe so far in first-in-human data. The drugs exert different effects on the receptor and soluble TREM2.
TREM2: A Chill Pill for Neurons?
In mouse models, the microglial receptor counteracts hyperexcitability. Both transmembrane and soluble TREM2 seem involved.
Moving Target: New Biology Casts TREM2 as a Shifty Mark
TREM2 on plaque-associated microglia becomes desensitized to agonist antibodies. The receptor may also calm hyperactive neurons.
New Partnership Forms to Harness AI for Alzheimer’s Research
Drawing in researchers in academia, pharma, and AI companies, a nascent consortium aims to speed up discoveries in complex diseases. Smaller AI projects report data at AD/PD.
Finally, PET Tracers For α-Synuclein Yield Signal in Idiopathic Parkinson’s
Several tracers detect the low level of α-synuclein aggregates present in sporadic disease. None are ready for clinical use.
Zapping the Zoster Virus, Dodging Dementia
Among people vaccinated against shingles in Wales, there were 20 percent fewer dementia diagnoses over the next seven years.
AD/PD™ 2025: Advances in Science & Therapy
Finally, PET Tracers For α-Synuclein Yield Signal in Idiopathic Parkinson’s New Partnership Forms to Harness AI for Alzheimer’s Research Moving Target: New Biology Casts TREM2 as a Shifty Mark TREM2: A Chill Pill for Neurons? Trialists Grapple with How to
Current Filters
- Date Range : Jan 2025 to Apr 2025 x